CN102335128A - Formula and preparation method of iodine complex solution - Google Patents
Formula and preparation method of iodine complex solution Download PDFInfo
- Publication number
- CN102335128A CN102335128A CN201110179136XA CN201110179136A CN102335128A CN 102335128 A CN102335128 A CN 102335128A CN 201110179136X A CN201110179136X A CN 201110179136XA CN 201110179136 A CN201110179136 A CN 201110179136A CN 102335128 A CN102335128 A CN 102335128A
- Authority
- CN
- China
- Prior art keywords
- iodine
- preparing
- solution
- add
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 239000011630 iodine Substances 0.000 title claims abstract description 74
- 229910052740 iodine Inorganic materials 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000009472 formulation Methods 0.000 title 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008213 purified water Substances 0.000 claims abstract description 19
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 13
- GNMOPZKSTPABSN-UHFFFAOYSA-N dimethoxymethane;propane-1,2,3-triol Chemical compound COCOC.OCC(O)CO GNMOPZKSTPABSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 11
- 238000003756 stirring Methods 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 239000000645 desinfectant Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 3
- 238000010668 complexation reaction Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940051841 polyoxyethylene ether Drugs 0.000 claims 2
- 229920000056 polyoxyethylene ether Polymers 0.000 claims 2
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 claims 1
- 241000238370 Sepia Species 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 44
- 230000001954 sterilising effect Effects 0.000 abstract description 14
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000012895 dilution Substances 0.000 abstract description 2
- 238000010790 dilution Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 238000005070 sampling Methods 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 4
- 210000004247 hand Anatomy 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000012422 test repetition Methods 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a formula and a preparation method of an iodine complex solution. The formula comprises the specific components of 1-6 percent of iodine, 1-5 percent of potassium iodide, 20-40 percent of surface active agent, 5-20 percent of glycerol dimethoxymethane, 10-20 percent of glycerol, 0.2-0.4 percent of phosphoric acid and the balance of purified water. Because the surface active agent, the glycerol and the glycerol dimethoxymethane are used in the iodine complex solution, thus the iodine complex solution has the characteristics of strong stability, longer storage period, more thorough sterilization, large dilution factor, small consumption, high content of effective iodine, and the like; and the preparation method is simple and is suitable for industrialized production.
Description
Technical field:
The present invention relates to the solution formula and the method for preparing in medical disinfectant field, particularly a kind of chelated iodine.
Background technology:
The sterilization mechanism of Operand is microbial cell parietal layer albumen configuration is changed cause membrane permeability to increase, and causes mitochondrion to destroy then, and respiratory enzyme suppresses; Energy metabolism impairment takes place, and material in direct oxidation and the halogenation endochylema destroys the cell inner structure; Dna replication dna with transcribe obstacle; Cause spore swelling, distortion, depression or local damage, and can cause the destruction of chitinous layer and cortical layer permeability barrier, cause DPA, DNA, RNA etc. to spill.Cause also that simultaneously glucose-6-phosphate dehydrogenase (G6PD) in the thalline, lactic acid dehydrogenase, alkaline phosphatase activity descend, influence the transmission and proteinic the synthesizing of hereditary information, cause fungal cell's final death.
At present, on the market be that the disinfectant of main component has much with iodine, like iodine tincture solution, povidone iodine, betagen solution, iodine complex disinfection solution, double-chain quaternary ammonium salt chelated iodine solution or the like, that play main effect is effective I; Because iodine is more active element, as easy as rolling off a log volatilization makes most shelf-life of this type of Operand shorter; At present, Operand effect duration of domestic production is not wait in 0.5～2 year, and difference is bigger; And its content is generally lower, general 0.1%～1%; Curative effect reduces, and quality is unstable, can not satisfy the multi-purpose demand of Operand.
Summary of the invention:
The purpose of this invention is to provide a kind of stable chelated iodine solution, another purpose provides a kind of method for preparing of high concentration chelated iodine,
Chelated iodine solution long shelf-life of the present invention, stability are by force, concentration is high, consumption is little, medicinal liquid prolonged in the sterilization position time of staying, and antibacterial is thorough, and side effect reduces, and can significantly improve the disinfectant of sterilization and bactericidal effect.
For realizing above-mentioned purpose, the technical scheme of employing is: iodine 1～5%, potassium iodide 4～8%, surfactant 10～20%, stabilizing agent 20～40%, phosphoric acid 0.2～0.5%, purified water 35～65%.
The method for preparing of chelated iodine solution of the present invention comprises the steps:
After getting surfactant, glycerin, glycerin methylal and an amount of purified water mixing, stir, add potassium iodide, after the stirring and dissolving; Add iodine, stirring and dissolving stirs 1～2h, 50～60 ℃ of insulation arrest reaction 4～6h; Be cooled to below 25 ℃, stir, add between the phosphoric acid regulating ph value 6.0～8.0, qualified after; Add purified water to full dose, packing gets final product.
Compared with prior art, the present invention has the advantage of following aspect:
1. available iodine content of the present invention is 1～8%; And the chelated iodine solution available iodine on the market is 0.1～1%, and betagen solution available iodine 0.1～1% is during particularly as the sterilization of mucosa, wound and wound surface flushing; Its concentration is high, extension rate is bigger, and consumption is little.
2. on original chelated iodine basis, increased surfactant and stabilizing agent owing to the present invention, extension of validity, stability improves, and the tool test shows that chelated iodine solution is through 37 ℃ of placement 90d, and the available iodine content rate of descent on average is merely 1.47%.
3. the chelated iodine solution of the present invention preparation, pH value has Mucocutaneous PH to be close 6.0～8.0, and is less to skin and mucous membrane irritation property.
4. the chelated iodine solution of the present invention preparation, direct disinfecting surface not only, and can add an amount of water and dilute, be used for irrigation and disinfections such as tract, fistula.
5. the chelated iodine solution of the present invention's preparation is surfactant and iodine generation complexation, because the existence of surfactant can be disappeared the color of iodine automatically, need not take off iodine.
6. method for preparing of the present invention is simple, does not need special agitated reactor, and the used time of whole process of production shortens, and is convenient to operational applications in the production practices, can large-scale production.
The chelated iodine solution disinfection effect test of the present invention's preparation:
For understanding its bactericidal property and toxicity, experimental study has been carried out at the scene that under laboratory condition, reaches.As follows with the result of study report at present.
1 method
1.1 bacteria suspension preparation
Depletion Staphylococcus aureus (ATCC 6538), escherichia coli (8099), Pseudomonas aeruginosa (ATCC 15442), the fresh slant culture of Candida albicans (ATCC 10231) 24h wash and are mixed with the test organisms suspension with diluent.During test bacteria suspension and 3% bSA are done half-and-half dilution.
1.2 nertralizer is selected test
Test is represented with staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans, designs 6 groups of tests, is undertaken by suspension quantitative disinfecting test program.By " disinfection technology standard " version specified standard in 2002 result of determination.
1.3 suspension quantitative disinfecting test
Chelated iodine solution is mixed with 1.25 times of experimental concentration, in sterile test tube, adds the bacteria suspension that 1mL contains bSA, place 20 ℃ of water-bath constant temperature in the lump.In vitro add 4mL chelated iodine solution, mixing immediately containing bacteria suspension then; Act on to the stipulated time, get 0.5mL and be added to and contain the 4.5mL nertralizer in vitro, mixing.Carry out count plate in the lump together with positive controls, calculate and kill logarithm value.Test repetition 3 times.
1.4 energy test
With standard hard water chelated iodine solution being mixed with 3 groups of gradient experimental concentration, is test organisms with escherichia coli, operates by the energy test procedure of " disinfection technology standard " version regulation in 2002.Test repetition 3 times.
1.5 hands and skin on-site disinfection test and stability test
Select 30 volunteers, make an experiment in the forearm inboard.Before the sterilization, a side is carried out the matched group sampling, wipe away in the forearm inboard with aseptic cotton and smear sampling.Bedew this disinfectant solution that contains available iodine 5000mg/L with sterile gauze then both arms are carried out the wiping sterilization, effect 3min, the aseptic cotton of reuse is wiped away and smears sampling after the adhesional wetting nertralizer carries out disinfection.The hands sterilization is to get both hands to refer to the face of bending, and a side is done the preceding sampling of sterilization; Use then and this disinfectant solution wiping sterilization of arm same concentrations, effect 3min, sample to other the 1 side finger face of bending in the sterilization back.Test group and positive control sampling BIAO and BEN are carried out count plate, calculate natural bacteria is killed logarithm value.
Stability test is that chelated iodine solution stock solution is deposited 90d under 37 ℃ of conditions, and its available iodine content of sampling and measuring calculates its content rate of descent before and after depositing.
1.6 toxicity test
1.6.1 acute oral toxicity test
Get 20 of the healthy Kunming mouses of 18～21g body weight, male and female half and half.The employing maximum limit is mensuration, establishes dose groups of 5000mg/kg.bw, the disposable gastric infusion of per os.After the administration, observe animal poisoning symptom and death condition, in continuous 2 weeks, calculate LD
50
1.6.2 skin irritation test
Adopt the test of one whole skin irritation, plant white rabbit with Holland, each the QUMAO 3cm * 3cm area of rabbit back both sides of being in spreads upon on side 2.5cm * 2.5cm skin with the chelated iodine solution 0.5mL of available iodine 5000mg/L, and opposite side is contrast with the distilled water.Flush away behind the coating 4h is observed the skin irritation reaction in 1h, 24h, 48h.Calculating stimulates integration, makes an appraisal.
1.6.3 PCEMNR micronucleus test
Get 50 of body weight 25～30g mices, be divided into 5 groups at random, 10 every group, male and female half and half.3 dose groups such as design 5000,2500,500mg/kg.bw and feminine gender and positive controls (40mg/kg.bw cyclophosphamide) are pressed the 0.2mL/10g body weight, divide (24h at interval) per os gastric infusion 2 times.6h puts to death animal after the last administration, gets bone marrow of sternum, smear, fixing, dyeing, and microscopy bone marrow polychromatic erythrocyte, every animal is checked 1000, record micronucleus cell number calculates micronuclear rates, through statistical analysis.
2 results
2.1 nertralizer qualification test result
Result of the test shows, with the nertralizer that 5g/L sodium thiosulfate and 5g/L tween 80 and 1g/L lecithin are formed, the chelated iodine solution of the highest experimental concentration of can effectively neutralizing has no adverse effects to test organisms and culture medium to the test organisms residual action.
2.2 bactericidal effect
The result shows that to contain the chelated iodine solution of available iodine 250mg/L, to staphylococcus aureus, escherichia coli, Pseudomonas aeruginosa 1.5min action time in the suspension, killing rate is 100%; To the Candida albicans killing rate is 99.99% (table 1).
Table 1 chelated iodine solution bactericidal effect
Annotate: available iodine content is 200mg/L
2.3 energy test and stability test result
3 repeated trials, the result shows that it is available iodine 250mg/L (table 2) that chelated iodine solution is tested minimum certified concentration to the escherichia coli energy.This chelated iodine solution stock solution stores 90d, available iodine content rate of descent average out to 1.47% through 37 ℃.
Table 2 chelated iodine solution energy result of the test
Annotate: it is 26600000cfu/mL that the test organisms suspension contains the bacterium number.
2.4 on-site disinfection test result
Testing result shows, with chelated iodine solution stock solution 30 volunteer's handss and arm skin is carried out the wiping sterilization, and the natural bacteria elimination factor is reached more than 96%.
2.5 toxicity test result
Result of the test proves that chelated iodine solution is to chmice acute per os toxicity test available iodine LD
50＞10000mg/kg.bw belongs to actual nontoxic; To the skin nonirritant; There is not the micronucleus effect that causes.
3 discuss
Result of study shows that the chelated iodine solution of the present invention's preparation has the good sterilization effect, with available iodine 250mg/L effect 1.5min, can reach 100% to the bacterial propagule killing rate, and is better than similar sanitizer disinfecting effect.Chelated iodine solution really belongs to low toxicity, nonirritant disinfectant, can be widely used in the sterilization of skin mucosa.
The specific embodiment
Following case study on implementation is that the present invention is further specified.
Embodiment 1
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that formula proportion comprises following material:
Iodine 1.5%, potassium iodide 2%, NP-7 20%, glycerin methylal 5%, glycerin 10%, phosphoric acid 0.2%, purified water add to full dose (i.e. 100% amount).
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that method for preparing comprises:
After getting NP-7, glycerin, glycerin methylal and an amount of purified water mixing, stir, add potassium iodide, after the stirring and dissolving; Add iodine, stirring and dissolving, continuous stirring 1～2h, 50～60 ℃ of insulation arrest reaction 4～6h; Be cooled to below 25 ℃, stir, add between the phosphoric acid regulating ph value 6.0～8.0, qualified after; Add purified water to full dose, packing gets final product.
Embodiment 2.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that formula proportion comprises following material:
Iodine 2%, potassium iodide 2.5%, AEO-7 25%, glycerin methylal 5%, glycerin 15%, phosphoric acid 0.2%, purified water add to 100% capacity.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that method for preparing comprises:
After getting AEO-7, glycerin, glycerin methylal and an amount of purified water mixing, stir, add potassium iodide, after the stirring and dissolving; Add iodine, stirring and dissolving stirs 1～2h, 50～60 ℃ of insulation arrest reaction 4～6h; Be cooled to below 25 ℃, stir, add between the phosphoric acid regulating ph value 6.0～8.0, qualified after; Add purified water to full dose, packing gets final product.
Embodiment 3.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that formula proportion comprises following material:
Iodine 6%, potassium iodide 5%, AE0-7 10%, NP-9 30%, glycerin methylal 10%, glycerin 20%, phosphoric acid 0.2%, purified water are added to 100% capacity.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that method for preparing comprises:
After getting NP-9, AEO-7, glycerin, glycerin methylal and an amount of purified water mixing, stir, add potassium iodide, after the stirring and dissolving; Add iodine, stirring and dissolving stirs 1～2h, 50～60 ℃ of insulation arrest reaction 6h; Be cooled to below 25 ℃, stir, add between the phosphoric acid regulating ph value 6.0～8.0, qualified after; Add purified water to full dose, packing gets final product.
Embodiment 4.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that formula proportion comprises following material:
Iodine 6%, potassium iodide 5%, AEO-9 40%, glycerin methylal 10%, glycerin 10%, phosphoric acid 0.2%, purified water are added to 100% capacity.
The prescription and the method for preparing of the described a kind of chelated iodine solution of present embodiment is characterized in that method for preparing comprises:
After getting AEO-9, glycerin, glycerin methylal and an amount of purified water mixing, stir, add potassium iodide, after the stirring and dissolving; Add iodine, stirring and dissolving, continuous stirring 2h, 55 ℃ of insulation reaction 5h; Be cooled to below 25 ℃, stir, add between the phosphoric acid regulating ph value 6.5～7.5, qualified after; Add purified water to full dose, packing gets final product.
Above-described four embodiment are to explanation of the present invention; For a person skilled in the art; Under the prerequisite that does not break away from the principle of the invention; Can also further improve the present invention,, should belong to protection scope of the present invention so the equivalence that the every described method of scope, characteristic and principle according to patent of the present invention done changes or modifies.
Claims (6)
1. the prescription of a chelated iodine solution and method for preparing is characterized in that after iodine and the potassium iodide complexation, add surfactant, purified water, form stable iodine complex disinfection solution, and its available iodine content is 2～8%, and concrete composition proportion is following:
Iodine 1～5%, potassium iodide 1～5%, surfactant 10～40%, glycerin methylal 5～20%, glycerol 10～20%, phosphoric acid 0.2～0.4%, purified water adds to full dose.
2. according to right 1 requirement; Described chelated iodine solution; It is characterized in that used surfactant agent is one or both mixing in NPE or the fatty alcohol-polyoxyethylene ether; The series of NPE (NP) comprising: NP-7, NP-9, NP-10, NP-11, the series of fatty alcohol-polyoxyethylene ether (AEO) has: AEO-7, AEO-9, AEO-10, its consumption is 10%～40%.
3. according to right 1 requirement, the prescription of described chelated iodine solution and method for preparing is characterized in that its character of prepared disinfectant is brownish red or the uniform liquid of sepia thickness.
4. according to right 1 requirement, the prescription of described chelated iodine solution and method for preparing is characterized in that: can prepare according to following method:
Get surfactant, glycerol and glycerin methylal and mix, stir, add iodine and potassium iodide, stir 1～2h; 50～60 ℃ of insulation reaction 5～6h are cooled to below 25 ℃, stir, and add between the phosphoric acid regulating ph value 6.0～8.0; After qualified, add purified water to full dose, packing gets final product.
5. according to right 1 requirement, the prescription of described chelated iodine solution and method for preparing is characterized in that, the present invention is the high concentration disinfectant, and its available iodine content is 2～8%.
6. according to right 1 requirement, the prescription of described chelated iodine solution and method for preparing is characterized in that, are disinfectants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110179136XA CN102335128A (en) | 2011-06-29 | 2011-06-29 | Formula and preparation method of iodine complex solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110179136XA CN102335128A (en) | 2011-06-29 | 2011-06-29 | Formula and preparation method of iodine complex solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102335128A true CN102335128A (en) | 2012-02-01 |
Family
ID=45511233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110179136XA Pending CN102335128A (en) | 2011-06-29 | 2011-06-29 | Formula and preparation method of iodine complex solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335128A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103210958A (en) * | 2013-05-15 | 2013-07-24 | 上海宇昂新材料科技有限公司 | Aquaculture compound iodine solution and preparation method thereof |
| CN103222476A (en) * | 2013-05-15 | 2013-07-31 | 上海宇昂新材料科技有限公司 | Iodic acid solution for aquaculture and preparation method thereof |
| CN105646222A (en) * | 2014-11-24 | 2016-06-08 | 天津博克尼科技发展有限公司 | Method for producing polyglycerol fatty acid ester iodine complex |
| CN107595881A (en) * | 2017-09-30 | 2018-01-19 | 蚌埠科卫消毒药剂有限公司 | A kind of skin mucosa disinfectant and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111427A (en) * | 1993-11-19 | 1995-11-08 | 美国电报电话公司 | Network-accessible intelligent telephone service |
| CN101084749A (en) * | 2007-06-05 | 2007-12-12 | 孙保兴 | Betaine-bound iodine disinfectant |
-
2011
- 2011-06-29 CN CN201110179136XA patent/CN102335128A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111427A (en) * | 1993-11-19 | 1995-11-08 | 美国电报电话公司 | Network-accessible intelligent telephone service |
| CN101084749A (en) * | 2007-06-05 | 2007-12-12 | 孙保兴 | Betaine-bound iodine disinfectant |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103210958A (en) * | 2013-05-15 | 2013-07-24 | 上海宇昂新材料科技有限公司 | Aquaculture compound iodine solution and preparation method thereof |
| CN103222476A (en) * | 2013-05-15 | 2013-07-31 | 上海宇昂新材料科技有限公司 | Iodic acid solution for aquaculture and preparation method thereof |
| CN105646222A (en) * | 2014-11-24 | 2016-06-08 | 天津博克尼科技发展有限公司 | Method for producing polyglycerol fatty acid ester iodine complex |
| CN107595881A (en) * | 2017-09-30 | 2018-01-19 | 蚌埠科卫消毒药剂有限公司 | A kind of skin mucosa disinfectant and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104013573B (en) | Available iodine content is the liquid PVP-I of 5-12% | |
| JP3777499B2 (en) | Antifungal composition | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN109777639B (en) | Preparation for disinfecting and cleaning hard surface of air conditioner and general objects and preparation method thereof | |
| CN106421217B (en) | A kind of solution of benzalkonium chloride and preparation method thereof | |
| CN101313673B (en) | Corrosion protection preservative fluid for reliquiae, preparing method and application of the same | |
| CN113491709B (en) | Multifunctional high-efficiency compound disinfectant and preparation method thereof | |
| CN105411923A (en) | Natural broad-spectrum anticorrosion composition containing grapefruit seed extract and application thereof | |
| CN102318607A (en) | Complexly-formulated high-efficient germicidal composition | |
| CN102335128A (en) | Formula and preparation method of iodine complex solution | |
| CN101163492A (en) | Method of treating skin ulcers using oxidative reductive potential water solution | |
| CN108157358A (en) | A kind of thimerosal and preparation method thereof | |
| CN105342869A (en) | Composition with anticorrosion effect and preparation method and application thereof | |
| Qutieshat et al. | Antimicrobial irrigation solutions in root canal treatment: A glance at the past, the present, and the future | |
| CN109362797A (en) | Iodine disinfectant and preparation method thereof | |
| CN102218149A (en) | Medical ultrasonic couplant capable of disinfection and sterilization and preparation technology thereof | |
| WO2008061375A1 (en) | Antiseptic | |
| CN112891372B (en) | Hydrogen peroxide and nano-silver compound hand disinfectant and preparation method thereof | |
| CN106074343B (en) | A kind of disposable hand cleanser of thymol nanoparticle and preparation method thereof | |
| CN115517267B (en) | Composite iodine solution with high partition coefficient for cultivation and preparation method thereof | |
| CN102846489B (en) | Polyhexamethyleneguanidine hydrochloride iodine medicine bath liquid and preparation method thereof | |
| CN102308804A (en) | Sterilization composition | |
| DE69717604T2 (en) | OPTHALMOLOGICAL COMPOSITION, PRODUCTS CONTAINING IT AND METHOD FOR DISINFECTING AND / OR CLEANING CONTACT LENSES | |
| CN101984804B (en) | Corpse preservation solution and preparation method thereof | |
| CN113207905A (en) | Contact lens care composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120201 |